CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00591123
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:29.077092+00:00
Published At: 2021-10-01T00:00:00+00:00
Record Updated At: 2021-10-01
Results Posted At: 2021-10-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Unresectable Adenocarcinoma of the Esophagus", "Metastatic Adenocarcinoma of the Esophagus", "Unresectable Adenocarcinoma of Gastric Cardia", "Metastatic Adenocarcinoma of Gastric Cardia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-10-01"
protocolSection.identificationModule.nctId: "NCT00591123"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-10-01"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.